This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ramelet, A. A. Search for Related Content PubMed PubMed Citation Articles by Ramelet, A. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Clinical Benefits of Daflon 500 mg in the Most Severe Stages of Chronic Venous Insufficiency

Chronic venous insufficiency (CVI) affects a large number of people in Western countries, and is responsible for considerable inconvenience, discomfort, suffering, and costs.

Micronized purified flavonoid fraction (MPFF, 450 mg diosmin plus 50 mg hesperidin- Daflon 500 mg) is a potent venotropic drug used in the treatment of venous insufficiency. Pharmacological and clinical studies demonstrated the comprehensive mode of action of Daflon 500 mg: it increases venous tone, it improves lymph drainage, and it protects the microcircu lation. Clinical international, prospective, multicenter, randomized, controlled studies versus placebo studies documenting the effects of Daflon 500 mg in CVI at advanced stages with edema, skin changes, and venous leg ulcer are reviewed. In edema, one of the most frequent complaints of patients, Daflon 500 mg brings about a significant reduction in leg circumference, thanks to its capacity to inhibit inflammatory reactions and to decrease capillary hyperper meability. The rationale for the use of Daflon 500 mg for treatment of skin disorders and venous leg ulcer is its action on the microcirculation-damaging processes. Regarding skin changes, Daflon 500 mg has been shown to improve venous trophic disorders, like gravitational (stasis) dermatitis, and dermatofibrosclerosis. In venous leg ulcer, Daflon 500 mg's clinical efficacy has been demonstrated in addition to standard treatment or versus standard treatment alone.

Daflon 500 mg, thanks to its comprehensive mode of action on the veins, lymphatics, and microcirculation, is the method of choice not only in the early stages of CVI treatment, but also in the severe stages of this condition, in combination with compression treatment, scle rotherapy, and surgery if appropriate.

Angiology, Vol. 52, No. 1 suppl, S49-S56 (2001)
DOI: 10.1177/000331970105200107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Sanchez-Vazquez, G. Briseno-Rodriguez, E. G. Cardona-Munoz, F. J. Galvez-Gastelum, S. E. Totsuka-Sutto, and L. Garcia-Benavides Isosorbide Dinitrate Spray as Therapeutic Strategy for Treatment of Chronic Venous Ulcers Angiology, March 1, 2008; 59(1): 64 - 71. [Abstract] [PDF]

				M.R. Cesarone, G. Belcaro, S. Errichi, U. Cornelli, L. Pellegrini, I. Ruffini, B.M. Errichi, A. Ledda, G. Vinciguerra, A. Ricci, et al. Topical Heparin: New Observations Angiology, April 1, 2007; 58(1S): 16S - 20S. [Abstract] [PDF]

				U. Wollina, M. B. Abdel-Naser, and R. Mani A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 169 - 180. [Abstract] [PDF]

				A.N. Nicolaides Chronic Venous Disease and the Leukocyte-Endothelium Interaction: From Symptoms to Ulceration Angiology, November 1, 2005; 56(1_suppl): S11 - S19. [Abstract] [PDF]

				A. N. Nicolaides Chronic Venous Disease and the Leukocyte-Endothelium Interaction: From Symptoms to Ulceration Angiology, November 1, 2005; 56(6_suppl): S11 - S19. [Abstract] [PDF]

				G. Belcaro, M. R. Cesarone, and M. Dugall Microcirculatory Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel in Venous Insufficiency and Hypertension: New Clinical Observations Angiology, November 1, 2004; 55(6_suppl): S1 - S5. [Abstract] [PDF]